Gastrointestinal complications of pelvic radiotherapy: are they of any importance? | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Responses

Leading article

Gastrointestinal complications of pelvic radiotherapy: are they of any importance?

Free

Compose a Response to This Article

Compose Response

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

No

Please describe the competing interests

PLEASE NOTE:

A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.

I agree to and have read the terms and conditions for rapid responses and BMJ Privacy Notice *

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

Treatment of ischemia: another promising approach for gastrointestinal complications of radiation
Tsuyoshi Konishi
Published on: 23 January 2006

Published on: 23 January 2006
Treatment of ischemia: another promising approach for gastrointestinal complications of radiation
- Tsuyoshi Konishi, doctor
- Other Contributors:
  Toshiaki Watanabe, and Hirokazu Nagawa
Dear Sir:
We have read with great interest the review of gastrointestinal (GI) complications after pelvic radiotherapy by Andreyev (1). Andreyev emphasized importance of fibrosis as the underlying cause for most GI symptoms after radiotherapy, and concluded that reversal or prevention of fibrosis could be highly profitable in the treatment of this complication, referring several anti-fibrotic agents such as lipo...
Show More

Dear Sir:
We have read with great interest the review of gastrointestinal (GI) complications after pelvic radiotherapy by Andreyev (1). Andreyev emphasized importance of fibrosis as the underlying cause for most GI symptoms after radiotherapy, and concluded that reversal or prevention of fibrosis could be highly profitable in the treatment of this complication, referring several anti-fibrotic agents such as liposomal Cu/Zn superoxide dismutase (2). However, there is another important target for the treatment of this complication, that is, local ischemia.
Ischemia and fibrosis together play an important role in the development of chronic GI complications after radiotherapy. Histological examinations have revealed that radiation induces characteristic vascular damage in the bowel, including marked fibrin thrombi and destruction of the arterioles with subintimal thickening (3, 4). This vascular damage deteriorates local blood supply, and persistent local ischemia leads to diffuse fibrosis in lamina propria and submucosa of the bowel wall. Then, fibrosis in turn accelerates vascular damage and further worsens local ischemia (4). This malignant circle of local ischemia and fibrosis is the key mechanism by which GI complications chronically progress and finally lead to serious consequences such as massive bleeding or perforation. Therefore, prevention or reversal of local ischemia is another important approach for terminating this malignant cycle and suppressing the progression of fibrosis. Indeed, Jones et al reported the efficacy of hyperbaric oxygen for radiation proctitis refractory to conventional therapies, and the European Committee for Hyperbaric Medicine and EORTC consensus conference in 2001 recommended the use of hyperbaric oxygen in the management of radiation proctitis and enteritis (5, 6).On the other hand, deterioration of mucosal ischemia in the treatment of radiation proctitis could result in unexpected acceleration of the disease as we reported previously (3, 7 ).
We agree with Andreyev in that fibrosis is a promising target for the treatment of GI complications after radiotherapy. However, we advocate that local ischemia should be another important target as well as fibrosis. With acceptance on this point, a therapeutic approach from the both sides of this pathogenesis, namely, to suppress fibrosis and to supply oxygen in the tissue, would provide more successful outcome in the treatment of this disorder.
References
1.Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut 2005;54(8):1051-4.
2.Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003;21(13):2545-50.
3.Konishi T, Watanabe T, Kitayama J, Shibahara J, Nagawa H. Endoscopic and histopathologic findings after formalin application for hemorrhage caused by chronic radiation-induced proctitis. Gastrointest Endosc 2005;61(1):161-4.
4.Haboubi NY, Schofield PF, Rowland PL. The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol 1988;83(10):1140-4.
5.Pasquier D, Hoelscher T, Schmutz J, Dische S, Mathieu D, Baumann M, et al. Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. Radiother Oncol 2004;72(1):1-13.
6.Jones K, Evans AW, Bristow RG, Levin W. Treatment of radiation proctitis with hyperbaric oxygen. Radiother Oncol 2005.
7.Konishi T, Watanabe T, Nagawa H. Formalin application in the treatment of chronic radiation-induced hemorrhagic proctitis induces acute deterioration of mucosal blood flow. Dis Colon Rectum 2006, in press.
Copyright: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in GUT and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence
Conflict of interest: none.
Show Less

Conflict of Interest:
None declared.
- Back to top